The Technical Analyst
Molecular Templates Inc [MTEM]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Molecular Templates Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-6.01% $1.485
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 7.98 mill |
| EPS: | -1.800 |
| P/E: | -0.820 |
| Earnings Date: | May 12, 2024 |
| SharesOutstanding: | 5.37 mill |
| Avg Daily Volume: | 0.0628 mill |
| RATING 2024-04-18 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.820 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.14x |
| Company: PE -0.820 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.125 - 1.855 ( +/- 24.50%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-02 | Biotech Target N V | Buy | 250 000 | Common Stock |
| 2024-04-02 | Biotech Target N V | Buy | 769 334 | Common Warrants (right to buy) |
| 2024-04-02 | Biotech Target N V | Buy | 134 667 | Prefunded Warrants (right to buy) |
| 2024-04-02 | Lalande Kevin M. | Buy | 1 154 154 | Warrants (Right to Buy) |
| 2024-04-02 | Lalande Kevin M. | Buy | 402 077 | Pre-Funded Warrants (Right to Buy) |
| INSIDER POWER |
|---|
| 99.91 |
| Last 98 transactions |
| Buy: 16 322 736 | Sell: 222 785 |
Forecast:
16:00 - $1.485
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.485
Forecast 2: 16:00 - $1.485
Forecast 3: 16:00 - $1.485
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.485 (-6.01% ) |
| Volume | 0.0366 mill |
| Avg. Vol. | 0.0628 mill |
| % of Avg. Vol | 58.27 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MTEM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MTEM
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Last 10 Buy Signals
Latest Press Releases
2024-04-09 08:11:00 - Press Release
Molecular Templates Presents Interim Data From Mt-6402 Phase I Study In Patients With Pd-l1+ Solid Tumors At The 2024 American Association For Cancer Research (aacr) Annual Meeting; Monotherapy Activity In Checkpoint-experienced Head And Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism
Austin, texas, april 09, 2024 (globe newswire) -- molecular templates, inc. (nasdaq: mtem, “molecular templates,” or “mtem”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“etbs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today announced that mtem will present a poster, “first-in-human, dose escalation and expansion study of mt-6402, a novel engineered toxin body (etb) targeting pd-l1, in patients with pd-l1 expressing relapsed/refractory advanced solid tumors: interim data,” at the 2024 american association for cancer research annual meeting taking place in san diego, ca, and also announced monotherapy response activity in head and neck cancer.
2024-03-29 08:21:00 - Press Release
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results And Business Update
Austin, texas, march 29, 2024 (globe newswire) -- molecular templates, inc. (nasdaq: mtem, “molecular templates,” or “mtem”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“etbs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results for the fourth quarter and full year ended december 31, 2023.
2024-03-28 08:11:00 - Press Release
Molecular Templates Announces $9.5 Million Private Placement Offering And Agreement To Amend Second Tranche Of July 2023 Purchase Agreement
Austin, texas, march 28, 2024 (globe newswire) -- molecular templates, inc. (nasdaq: mtem, “molecular templates,” or “mtem”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, announced today it has entered into a definitive amended and restated securities purchase agreement with certain healthcare investors that will provide $9.5 million in gross proceeds to mtem through the closing of the second tranche of its previously announced july 2023 private placement and purchase agreement on amended terms...
2024-03-04 08:11:00 - Press Release
Molecular Templates, Inc. Provides Interim Update
Monotherapy activity with pd-l1-targeting mt-6402 in head and neck cancer; unique pharmacodynamic effects with ctla-4 targeting mt-8421 in on-going phase i study monotherapy activity with pd-l1-targeting mt-6402 in head and neck cancer; unique pharmacodynamic effects with ctla-4 targeting mt-8421 in on-going phase i study
2024-02-08 17:55:00 - Press Release
Molecular Templates To Present At Oppenheimer 34th Annual Healthcare Life Sciences Conference
Austin, texas, feb. 08, 2024 (globe newswire) -- molecular templates, inc. (nasdaq: mtem, “molecular templates,” or “mtem”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and differentiated mechanisms of action for cancer, announced participation in the upcoming oppenheimer 34th annual healthcare life sciences conference.
Latest News
2024-02-08 17:55:00 - GlobeNewsWire
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
AUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and differentiated mechanisms of action for cancer, announced participation in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference.
2023-11-01 16:12:00 - GlobeNewsWire
Molecular Templates to Participate in Upcoming Investor Conferences
AUSTIN, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies with potent differentiated mechanisms of action for cancer, today announced participation in the following upcoming investor conferences:
2023-08-25 10:31:52 - Zacks Investment Research
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Molecular Templates Inc. (MTEM)
Molecular Templates Inc. (MTEM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
2023-05-26 17:10:00 - GlobeNewsWire
Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
AUSTIN, Texas, May 26, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, announced today the presentation of a poster at the American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place June 2-6, 2023 in Chicago, IL. One-on-one meetings may be scheduled directly with Molecular Templates.
2023-04-05 11:48:12 - PennyStocks
9 Hot Penny Stocks Under $0.99 To Watch Right Now
Penny stocks to watch under $1 The post 9 Hot Penny Stocks Under $0.99 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-03-30 21:40:14 - Zacks Investment Research
Molecular Templates Inc. (MTEM) Reports Q4 Loss, Lags Revenue Estimates
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -56% and 63.99%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2023-03-10 08:01:57 - InvestorPlace
Why Is Molecular Templates (MTEM) Stock Up 36% Today?
Molecular Templates (NASDAQ: MTEM ) stock is rocketing higher on Friday after the company got approval from the FDA. That FDA approval has to do with its IND application for its cancer treatment.
2023-03-01 16:44:00 - GlobeNewsWire
Molecular Templates Announces Participation in Upcoming Conferences
AUSTIN, Texas, March 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies with potent differentiated mechanisms of action for cancer, announced participation in the following upcoming 2023 conferences:
2022-12-02 17:02:00 - GlobeNewsWire
Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting
AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that they will present a poster on interim clinical results for the MT-5111 program at the San Antonio Breast Cancer Symposium (SABCS) which will take place December 6 – December 10, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, TX. Molecular Templates will also participate in one-on-one meetings at the 64th American Society of Hematology (ASH) Annual Meeting which will take place December 10 – December 13, 2022 at the Ernest N...
2022-11-23 16:30:00 - GlobeNewsWire
Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI's 5th Annual HealthCONx Conference and Piper Sandler's 34th Annual Healthcare Conference
AUSTIN, Texas, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that CEO, Eric Poma, Ph.D., will present a virtual fireside chat at Evercore ISI's 5th Annual HealthCONx conference which will take place November 29 – December 1, 2022, and an in-person fireside chat with an analyst Q&A portion at Piper Sandler's 34th Annual Healthcare Conference in New York, NY which will take place November 29 – December 1, 2022. Highlighting positive incremental data, the chats will comprise a review of the de-immunized next-generation ETB scaffold and programs...